FDA recall record

AbbVie AndroGel (testosterone gel) 1.62%, 88 gm metered-dose pump, 20.25 mg of testosterone recall — FDA D-0033-2018

Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

Class IIIclassification
D-0033-2018official record ID
Nov 1, 2017report date

Recall record at a glance

Official recordD-0033-2018
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmAbbVie Inc.
Report dateNov 1, 2017
Recall initiation dateSep 8, 2017
Quantity520 pumps
LocationNorth Chicago, IL, United States

Official product description

AndroGel (testosterone gel) 1.62%, 88 gm metered-dose pump, 20.25 mg of testosterone per pump actuation, 60 metered pump actuations, Rx Only, Marketed by: AbbVie Inc., North Chicago, IL 60064 USA. NDC: 0051-8462-33

Why the product was recalled

Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

Distribution information

AZ

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugNov 15, 2023

SYNTHROID recall — FDA D-0088-2024

Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

Class IIIFDA: OngoingAbbVie Inc.
DrugMar 8, 2017

Duopa recall — FDA D-0495-2017

Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing…

Class IIFDA: TerminatedAbbVie Inc.
DrugMay 7, 2014

Lupron Depot recall — FDA D-1287-2014

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Class IIFDA: TerminatedAbbVie Inc.
DrugMay 7, 2014

Lupron Depot recall — FDA D-1291-2014

Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device.

Class IIFDA: TerminatedAbbVie Inc.